Theaflavins are compounds from black tea, studied mainly for lowering "bad" cholesterol. One strong trial supports this; another using a purer form found no effect, so it stays uncertain. Weaker signals touch blood sugar, weight, and antioxidant status. Barely absorbed, they likely act in the gut. Well tolerated, low-cost, but unproven. (Full Review)

Protocol

Standard Dose

~375 mg extract daily

Delivering ~75 mg theaflavins, once daily

Timing

With a meal

Improves tolerability and coincides with dietary fat absorption; caffeinated extracts earlier in the day

Beverage Alternative

Several cups black tea daily

Lower-intensity, food-based route used in cardiovascular population studies

Time to effect

LDL Cholesterol

8–12 weeks

Measurable LDL reductions seen over 12 weeks; recheck lipids after 8–12 weeks of consistent use

Glucose & Triglycerides

~12 weeks

Black tea trial reported reduced fasting glucose and triglycerides over 12 weeks

Body Weight

Several weeks

Black tea extract trials reported small weight reductions over several weeks

Benefits

Medium: LDL cholesterol reduction

Low: Improved glucose and lipid metabolism; weight and body fat support; antioxidant status and LDL oxidation resistance

Speculative: Cardiovascular and longevity support; anticancer effects; antiviral and antimicrobial activity

Contraindications

Pregnancy and breastfeeding

Children

Iron-deficiency anemia

Significant liver disease (Child-Pugh Class B or C)

Scheduled surgery

Key Interactions

Iron supplements and iron-rich meals

Cholesterol-lowering agents (statins, ezetimibe, bile acid sequestrants, plant sterols)

Blood-sugar-lowering agents (metformin, sulfonylureas, acarbose)

Absorption-dependent oral medications

Stimulant or caffeine-containing supplements

Risk & Side Effects

Low: Gastrointestinal upset; reduced iron absorption

Speculative: Liver concerns at high doses; drug interaction via absorption interference

Monitoring

Marker	Target	Why
LDL Cholesterol (LDL-C)	< 100 mg/dL (lower for high cardiovascular risk)	Primary target of theaflavins' proposed cholesterol effect
Total Cholesterol	< 200 mg/dL	Tracks overall response alongside LDL
HDL Cholesterol (HDL-C)	> 50 mg/dL (women), > 40 mg/dL (men)	Ensures intervention is not adversely shifting the ratio
Triglycerides	< 100 mg/dL (optimal); conventional cutoff < 150 mg/dL	Secondary metabolic marker that may improve
Fasting Glucose	70–90 mg/dL (functional); conventional normal < 100 mg/dL	Detects any glucose-handling benefit, relevant if metabolic goal
Ferritin	50–150 ng/mL (functional)	Guards against iron depletion from polyphenol-iron binding
ALT / AST	ALT < 25 U/L (women), < 33 U/L (men) functional	Screens for the rare liver concern carried over from high-dose catechin extracts

Cadence: Baseline, then at ~12 weeks, then every 6–12 months if continued; more frequent lipid checks if combined with prescription cholesterol- or glucose-lowering medication.

Qualitative Assessment

Digestive comfort (absence of nausea or stomach upset with dosing)
Energy levels and any caffeine-related effects if a caffeinated extract is used
Sleep quality, particularly if using a black tea extract that may contain caffeine
Overall adherence and tolerability over the 12-week assessment window

Theaflavins for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment